• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Almac Group Announces Support of Agios' PYRUKYND®


Almac Group confirms it has supported Agios Pharmaceuticals, Inc., in the clinical trial and commercial launch of PYRUKYND® (mitapivat).

The treatment is the first FDA approved, disease-modifying therapy for adults with hemolytic anemia caused by PK deficiency, a rare, debilitating, and lifelong form of anemia.

Read more about the work between Almac Group and Agios here.

Related Videos
Related Content